DOCSLIB.ORG

The Effect of the Polyadenylation Inhibitor Cordycepin on MCF-7 Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of the Polyadenylation Inhibitor Cordycepin on MCF-7 Cells The effect of the polyadenylation inhibitor Cordycepin on MCF-7 cells Asma Khurshid, MSc (University of Nottingham) Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy July 2015 Declaration Except where acknowledged in the text, I declare that this dissertation is my own work and is based on research that was undertaken by me in the School of Pharmacy, Faculty of Science, University of Nottingham. i Abstract Cordycepin (3′-deoxyadenosine) is a medicinal bioactive component of the caterpillar fungi (Cordyceps and Ophicordyceps). It is reported to have nephroprotective, antiapoptotic, anti-metastatic, hepatoprotective (Yue et al. 2013), inflammatory effects, antioxidant, anti-tumor, immunomodulatory and vasorelaxation activities. Cordycepin is well known to terminate and inhibit polyadenylation, both in vitro and in vivo. Other proposed mechanisms of action of cordycepin include activation of adenosine receptors, activation of AMP dependent kinase (AMPK) and inhibition of PARP1. The purpose of this study is to elucidate the biological and pharmacological effects of cordycepin on cancer cell lines such as MCF-7 cells. In this study I found that cordycepin reduces the cell proliferation in all examined cell lines without always exerting an effect on 4EBP phosphorylation and protein synthesis rates. Therefore, the effects on protein synthesis via inhibition of mTOR, which were previously reported, are not only the sole reason for the effect of cordycepin on cell proliferation. Knockdown of poly (A) polymerases reduces cell proliferation and survival, indicating that poly (A) polymerases are potential targets of cordycepin. I studied different adenosine analogues and found that 8 aminoadenosine, the only one that also consistently inhibits polyadenylation, also reduces levels of P-4EBP. It also inhibits the expression of specific genes indicating that the effects on polyadenylation, mTOR signalling and gene expression are linked. Also consistent with polyadenylation inhibition as the major mode of action is the fact that the effects of cordycepin on gene expression are predominantly post-transcriptional. However, knockdown of poly (A) polymerases did not have the same effects on gene expression or on polyadenylation, indicating that cordycepin may act as a dominant negative rather than as a null mutant. This is consistent with the fact that cordycepin is known to arrest a normally transient polyadenylation complex. We performed microarray analysis of cordycepin treated MCF-7 cells and found that the downregulated mRNAs were predominantly involved in transcriptional regulation, cell proliferation, cell cycle and cell migration. These data show that ii cordycepin is a promising new drug for cancer and indicates that the mode of action it is likely to be through the inhibition of polyadenylation. iii Acknowledgements Firstly, I would like to thank to my supervisor Dr Cornelia H. de Moor for her great support, time, encouragement and co operation throughout my studies. It would not be possible for me to finish off my work without her understanding of my responsibilities being a mother and a student. I do not have enough words to convey my deepest thanks to her. I would also like to thank to Keith Spriggs for his advice and guidance during my studies and especially to Catherine Jopling for helping me to carry out my radiation work safely and efficiently in a friendly manner. I also liked to convey my deepest thanks to Anne Willis and her team (MRC Toxicology unit, Leicester) for her support in performing microarray analysis for this project. I would also like to thank to all of the past and present members of the RNA biology and gene regulation group, for their support and making my time enjoyable during the work particularly Hannah Parker, Hughes Alexandra and Andrew Lewis for their support, enjoyable chats and help during the work. Special thanks to Alexander Kondrashov for not only helping me in experimental work with great experience and expertise over the past three years but also for his conceptual guidance. I would like to thank to my family especially to my father for being supportive, encouraging and for having faith in my capabilities. I would always remain thankful to my late grandmother for her kindness, care and love which will always remain in my heart. Thanks to University of Nottingham for funding support. Lastly, love to my daughters Ayra and Arfa who always reminds me a cheerful and enjoyable face of life with her love, hug and endurable smiles which not only gives me strength but also boost up my energy after many sleepless nights especially during my final stages of research work. iv Table of content Declaration ........................................................................................................... i Abstract ............................................................................................................... ii Acknowledgements ............................................................................................. iv Table of content .................................................................................................. v List of Figures ...................................................................................................... xi List of Tables ...................................................................................................... xiii List of Abbreviations .......................................................................................... xiv 1 Introduction ................................................................................................. 1 1.1 Breast cancer ......................................................................................... 1 1.1.1 Molecular subtypes of breast cancer ..................................................... 1 1.1.2 Role of receptors in Breast cancer ......................................................... 2 1.1.2.1 HER2 ................................................................................................ 2 1.1.2.2 Hormone receptors......................................................................... 3 1.1.3 Breast cancer treatment ........................................................................ 3 1.1.3.1 HER2+ treatment ............................................................................. 4 1.1.3.2 Endocrine therapy .......................................................................... 4 1.1.3.3 Chemotherapy ................................................................................ 5 1.1.4 Molecular mechanisms of breast cancer ............................................... 7 1.1.5 Breast cancer hallmarks ......................................................................... 8 1.1.5.1 Sustaining proliferative signaling .................................................... 8 1.1.5.2 Evading growth suppressors ........................................................... 8 1.1.5.3 Capable of replicative immortality ................................................. 9 1.1.5.4 Activating invasion and metastasis ................................................. 9 1.1.5.5 Inducing angiogenesis ................................................................... 10 1.1.5.6 Resisting cell death ....................................................................... 10 1.1.6 Mutational analysis of human breast cancers: Role of tumour suppressor and oncogenes ................................................................................. 11 1.1.6.1 Breast cancer mutations ............................................................... 12 1.2 Signal transduction by the insulin and growth factor pathways in breast cancer 13 1.2.1 Role of tyrosine kinase receptors ........................................................ 13 1.2.1.1 EGFR signaling in breast cancer .................................................... 14 v 1.2.1.1.1 Types of EGFR ............................................................................ 14 1.2.1.1.2 Types of EGFR ligands ................................................................ 15 1.2.1.1.3 Mode of receptor activation ..................................................... 15 1.2.1.1.4 EGFR mutations in breast cancer .............................................. 16 1.2.1.1.4.1 Role of HER2 ........................................................................ 16 1.2.1.2 Downstream signaling of EGFR ..................................................... 17 1.2.1.2.1 The PI3K/AKT/mTOR pathway ................................................... 19 1.2.1.2.1.1 What is mTOR ..................................................................... 19 1.2.1.2.1.2 Multi-protein complexes of mTOR ..................................... 19 1.2.1.2.1.2.1 mTORC2 ........................................................................ 20 1.2.1.2.1.2.2 mTORC1 ........................................................................ 20 1.2.1.2.1.3 Phosphatidylinositol 2-kinases ........................................... 20 1.2.1.2.1.4 Regulation of mTORC1 by upstream kinases ...................... 21 1.2.1.2.1.4.1 TSC mediated RHEB pathway ....................................... 21 1.2.1.2.1.4.2 AKT: A positive regulator of mTORC1 activity .............. 22 1.2.1.2.1.4.3 AMPK: A negative regulator of mTORC1 activity ........ 23 1.2.1.2.1.5 Downstream signaling of mTOR ......................................... 24 1.2.1.2.1.5.1 eIF4E/4E-BP .................................................................
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Supplementary Materials
    1 Supplementary Materials: Supplemental Figure 1. Gene expression profiles of kidneys in the Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice. (A) A heat map of microarray data show the genes that significantly changed up to 2 fold compared between Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice (N=4 mice per group; p<0.05). Data show in log2 (sample/wild-type). 2 Supplemental Figure 2. Sting signaling is essential for immuno-phenotypes of the Fcgr2b-/-lupus mice. (A-C) Flow cytometry analysis of splenocytes isolated from wild-type, Fcgr2b-/- and Fcgr2b-/-. Stinggt/gt mice at the age of 6-7 months (N= 13-14 per group). Data shown in the percentage of (A) CD4+ ICOS+ cells, (B) B220+ I-Ab+ cells and (C) CD138+ cells. Data show as mean ± SEM (*p < 0.05, **p<0.01 and ***p<0.001). 3 Supplemental Figure 3. Phenotypes of Sting activated dendritic cells. (A) Representative of western blot analysis from immunoprecipitation with Sting of Fcgr2b-/- mice (N= 4). The band was shown in STING protein of activated BMDC with DMXAA at 0, 3 and 6 hr. and phosphorylation of STING at Ser357. (B) Mass spectra of phosphorylation of STING at Ser357 of activated BMDC from Fcgr2b-/- mice after stimulated with DMXAA for 3 hour and followed by immunoprecipitation with STING. (C) Sting-activated BMDC were co-cultured with LYN inhibitor PP2 and analyzed by flow cytometry, which showed the mean fluorescence intensity (MFI) of IAb expressing DC (N = 3 mice per group). 4 Supplemental Table 1. Lists of up and down of regulated proteins Accession No.
    [Show full text]
  • Novocib Nucleoside Kinases
    PRECICE ® Services Information sheet Nucleoside kinases, rate-limiting step of nucleoside analogues activation Nucleoside analogues have proven to be a highly successful class of anti-cancer and anti-viral drugs. The therapeutic efficacy of nucleoside analogues is dependent of their intracellular phosphorylation. Two cellular nucleoside kinases, deoxycytidine kinase (dCK) and UMP-CMP kinase (CMK) are critical for phosphorylation of cytidine analogues. These kinases provide two first steps of activation of highly effective anti-cancer and anti-viral drugs, such as 1-β-D- arabinofuranosylcytosine (araC, aracytidine ), 2’,2’difluorodeoxycytidine (dFdC, gemcitabine ), β-D-2’3’- dideoxycytidine (ddC). Both kinases phosphorylate unnatural L-nucleosides (e.g., β-L-2’3’-dideoxy-3’thiacytidine, L- SSdC, 3-TC or lamividune ). Kinetic constants of araC, dFdC and 3TC phosphorylation by recombinant dCK and UMP-CMPK have been published. The comparison of phosphorylation properties of new nucleoside analogues with those of known drugs provides the rational basis for selection of analogues of better therapeutic potential. To characterize the phosphorylation properties of new nucleoside analogues, Novo CIB has developed human recombinant dCK and human recombinant CMK nucleoside phosphorylation assays. As shown in Table 1, CMK assay must be performed with monophosphate forms of nucleoside analogues and requires preliminary phosphorylation of nucleoside analogues and their purification. To circumvent this time-consuming step, NovoCIB has developed a coupled dCK-CMK nucleoside phosphorylation assay that delivers in one step the critical information on both dCK and CMK substrate properties of nucleoside analogue. Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a purine nucleoside analogue with a broad-spectrum antiviral activity.
    [Show full text]
  • Cordycepin for Health and Wellbeing: a Potent Bioactive Metabolite of an Entomopathogenic Medicinal Fungus Cordyceps with Its Nutraceutical and Therapeutic Potential
    molecules Review Cordycepin for Health and Wellbeing: A Potent Bioactive Metabolite of an Entomopathogenic Medicinal Fungus Cordyceps with Its Nutraceutical and Therapeutic Potential Syed Amir Ashraf 1, Abd Elmoneim O. Elkhalifa 1 , Arif Jamal Siddiqui 2 , Mitesh Patel 3 , Amir Mahgoub Awadelkareem 1, Mejdi Snoussi 2,4 , Mohammad Saquib Ashraf 5 , Mohd Adnan 2,* and Sibte Hadi 6,* 1 Department of Clinical Nutrition, College of Applied Medical Sciences, University of Hail, Hail PO Box 2440, Saudi Arabia; [email protected] (S.A.A.); [email protected] (A.E.O.E.); [email protected] (A.M.A.) 2 Department of Biology, College of Science, University of Hail, Hail PO Box 2440, Saudi Arabia; [email protected] (A.J.S.); [email protected] (M.S.) 3 Bapalal Vaidya Botanical Research Centre, Department of Biosciences, Veer Narmad South Gujarat University, Surat 395007, Gujarat, India; [email protected] 4 Laboratory of Bioresources: Integrative Biology and Valorization, (LR14-ES06), University of Monastir, Higher Institute of Biotechnology of Monastir, Avenue Tahar Haddad, BP 74, Monastir 5000, Tunisia 5 Department of Clinical Laboratory Sciences, College of Applied Medical Science, Shaqra University, Al Dawadimi PO Box 17431, Saudi Arabia; [email protected] 6 School of Forensic and Applied Sciences, University of Central Lancashire, Preston PR1 2HE, UK * Correspondence: [email protected] (M.A.); [email protected] (S.H.); Tel.: +966-533-642-004 (M.A.); +44-1772-894-395 (S.H.) Academic Editors: Simona Fabroni, Krystian Marszałek and Aldo Todaro Received: 25 May 2020; Accepted: 10 June 2020; Published: 12 June 2020 Abstract: Cordyceps is a rare naturally occurring entomopathogenic fungus usually found at high altitudes on the Himalayan plateau and a well-known medicinal mushroom in traditional Chinese medicine.
    [Show full text]
  • Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
    1318 Vol. 10, 1318–1325, February 15, 2004 Clinical Cancer Research Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients Rafael Rosell,1 Kathleen D. Danenberg,2 from bronchoscopy by real-time quantitative reverse tran- Vincente Alberola,3 Gerold Bepler,4 scription-PCR. Results were correlated with survival using Jose Javier Sanchez,5 Carlos Camps,6 the Kaplan-Meier method. 7 8 Results: A total of 100 patients were assessed. There was Mariano Provencio, Dolores Isla, a strong correlation between RRM1 and ERCC1 mRNA 1 9 P < 0.001). In the ;0.410 ؍ Miquel Taron, Pilar Diz, and expression levels (Spearman r Angel Artal10 on behalf of the Spanish Lung gemcitabine/cisplatin arm, patients with low RRM1 mRNA Cancer Group expression levels had significantly longer median survival 1Medical Oncology Service, Institut Catala`d’Oncologia, Hospital than those with high levels [13.7 versus 3.6 months; 95% -Me .[0.009 ؍ Germans Trias i Pujol, Barcelona, Spain; 2Response Genetics Inc, confidence interval (CI), 9.6–17.8 months; P Los Angeles, California; 3Medical Oncology Service, Hospital Arnau dian survival was also significantly longer among patients 4 de Vilanova, Valencia, Spain; Thoracic Oncology Program, H. Lee with low mRNA expression levels of both RRM1 and ERCC1 Moffitt Cancer Center and Research Institute, Tampa, Florida; 5 (not reached), than among those with high levels of both ؍ ,Facultat de Medicina, Autonomous University of Madrid, Madrid Spain; 6Medical Oncology Service, Hospital General de Valencia, genes (6.8 months; 95% CI, 2.6–11.1 months; P 0.016).
    [Show full text]
  • Supplementary File 2A Revised
    Supplementary file 2A. Differentially expressed genes in aldosteronomas compared to all other samples, ranked according to statistical significance. Missing values were not allowed in aldosteronomas, but to a maximum of five in the other samples. Acc UGCluster Name Symbol log Fold Change P - Value Adj. P-Value B R99527 Hs.8162 Hypothetical protein MGC39372 MGC39372 2,17 6,3E-09 5,1E-05 10,2 AA398335 Hs.10414 Kelch domain containing 8A KLHDC8A 2,26 1,2E-08 5,1E-05 9,56 AA441933 Hs.519075 Leiomodin 1 (smooth muscle) LMOD1 2,33 1,3E-08 5,1E-05 9,54 AA630120 Hs.78781 Vascular endothelial growth factor B VEGFB 1,24 1,1E-07 2,9E-04 7,59 R07846 Data not found 3,71 1,2E-07 2,9E-04 7,49 W92795 Hs.434386 Hypothetical protein LOC201229 LOC201229 1,55 2,0E-07 4,0E-04 7,03 AA454564 Hs.323396 Family with sequence similarity 54, member B FAM54B 1,25 3,0E-07 5,2E-04 6,65 AA775249 Hs.513633 G protein-coupled receptor 56 GPR56 -1,63 4,3E-07 6,4E-04 6,33 AA012822 Hs.713814 Oxysterol bining protein OSBP 1,35 5,3E-07 7,1E-04 6,14 R45592 Hs.655271 Regulating synaptic membrane exocytosis 2 RIMS2 2,51 5,9E-07 7,1E-04 6,04 AA282936 Hs.240 M-phase phosphoprotein 1 MPHOSPH -1,40 8,1E-07 8,9E-04 5,74 N34945 Hs.234898 Acetyl-Coenzyme A carboxylase beta ACACB 0,87 9,7E-07 9,8E-04 5,58 R07322 Hs.464137 Acyl-Coenzyme A oxidase 1, palmitoyl ACOX1 0,82 1,3E-06 1,2E-03 5,35 R77144 Hs.488835 Transmembrane protein 120A TMEM120A 1,55 1,7E-06 1,4E-03 5,07 H68542 Hs.420009 Transcribed locus 1,07 1,7E-06 1,4E-03 5,06 AA410184 Hs.696454 PBX/knotted 1 homeobox 2 PKNOX2 1,78 2,0E-06
    [Show full text]
  • The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells Zhao Yang1, Luyun He2,3, Kais
    The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells Zhao Yang1, Luyun He2,3, Kaisu Lin4, Yun Zhang1, Aihua Deng1, Yong Liang1, Chong Li2, 5, & Tingyi Wen1, 6, 1CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China 2Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China 3CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China 4Department of Oncology, the Second Affiliated Hospital of Soochow University, Suzhou 215000, China 5Beijing Jianlan Institute of Medicine, Beijing 100190, China 6Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, China Correspondence author: Tingyi Wen, e-mail: [email protected] Chong Li, e-mail: [email protected] Supplementary Figure S1. Isolation of human bladder cancer stem cells. BCMab1 and CD44 were used to isolate bladder cancer stem cells (BCSCs: BCMab1+CD44+) and bladder cancer non-stem cells (BCNSCs: BCMab1-CD44-) from EJ, samples #1 and #2 by flow cytometry. Supplementary Figure S2. Gene ontology analysis of downregulated genes of human BCSCs. (A) Pathway enrichment of 103 downregulated genes in BCSCs. (B) The seven downregulated genes in BCSCs participating in centromeric heterochromatin, mRNA-3’-UTR binding and translation regulator activity signaling pathways were validated by qRT-PCR. Data are presented as mean ± SD. P < 0.05; P < 0.01. Supplementary Figure S3. The expression of KMT1A is higher in human BC than that in peri-tumor tissues. (A) The expression of KMT1A was higher in BC samples than that in peri-tumors as assessed by immunohistochemistry, Scale bar = 50 m.
    [Show full text]
  • Coupled Biosynthesis of Cordycepin and Pentostatin in Cordyceps Militaris: Implications for Fungal Biology and Medicinal Natural Products
    85 Editorial Commentary Page 1 of 3 Coupled biosynthesis of cordycepin and pentostatin in Cordyceps militaris: implications for fungal biology and medicinal natural products Peter A. D. Wellham1, Dong-Hyun Kim1, Matthias Brock2, Cornelia H. de Moor1,3 1School of Pharmacy, 2School of Life Sciences, 3Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, UK Correspondence to: Cornelia H. de Moor. School of Pharmacy, University Park, Nottingham NG7 2RD, UK. Email: [email protected]. Provenance: This is an invited article commissioned by the Section Editor Tao Wei, PhD (Principal Investigator, Assistant Professor, Microecologics Engineering Research Center of Guangdong Province in South China Agricultural University, Guangzhou, China). Comment on: Xia Y, Luo F, Shang Y, et al. Fungal Cordycepin Biosynthesis Is Coupled with the Production of the Safeguard Molecule Pentostatin. Cell Chem Biol 2017;24:1479-89.e4. Submitted Apr 01, 2019. Accepted for publication Apr 04, 2019. doi: 10.21037/atm.2019.04.25 View this article at: http://dx.doi.org/10.21037/atm.2019.04.25 Cordycepin, or 3'-deoxyadenosine, is a metabolite produced be replicated in people, this could become a very important by the insect-pathogenic fungus Cordyceps militaris (C. militaris) new natural product-derived medicine. and is under intense investigation as a potential lead compound Cordycepin is known to be unstable in animals due for cancer and inflammatory conditions. Cordycepin was to deamination by adenosine deaminases. Much of the originally extracted by Cunningham et al. (1) from a culture efforts towards bringing cordycepin to the clinic have been filtrate of a C. militaris culture that was grown from conidia.
    [Show full text]
  • Staphylococcus Aureus Targets the Purine Salvage Pathway to Kill Phagocytes
    Staphylococcus aureus targets the purine salvage pathway to kill phagocytes Volker Winstela, Dominique Missiakasa, and Olaf Schneewinda,1 aDepartment of Microbiology, University of Chicago, Chicago, IL 60637 Edited by Emil C. Gotschlich, The Rockefeller University, New York, NY, and approved May 18, 2018 (received for review March 31, 2018) Staphylococcus aureus colonizes large segments of the human phagocyte clearance, suggesting that dAdo production represents population and causes invasive infections due to its ability to es- a general immune evasion mechanism for microbial pathogens cape phagocytic clearance. During infection, staphylococcal nucle- (16–18). However, the mechanisms whereby S. aureus-orother ase and adenosine synthase A convert neutrophil extracellular pathogen-derived dAdo is able to kill phagocytes is not known. traps to deoxyadenosine (dAdo), which kills phagocytes. The Here, we used a genome-wide CRISPR-Cas9 knockout screen mechanism whereby staphylococcal dAdo intoxicates phagocytes to identify genes required for dAdo intoxication. The results is not known. Here we used CRISPR-Cas9 mutagenesis to show suggest that S. aureus targets the purine salvage pathway to that phagocyte intoxication involves uptake of dAdo via the hu- eliminate host phagocytes. The identification of genes affecting man equilibrative nucleoside transporter 1, dAdo conversion to phagocyte intoxication may aid in the development of therapeutic dAMP by deoxycytidine kinase and adenosine kinase, and signal- strategies that can improve the outcome of MRSA infections. ing via subsequent dATP formation to activate caspase-3–induced cell death. Disruption of this signaling cascade confers resistance Results to dAdo-induced intoxication of phagocytes and may provide ther- A CRISPR-Cas9 Screen Identifies Genes Contributing to Deoxyadenosine apeutic opportunities for the treatment of infections caused by Intoxication of Phagocytes.
    [Show full text]
  • Cordycepin Inhibits Virus Replication in Dengue Virus-Infected Vero Cells
    molecules Article Cordycepin Inhibits Virus Replication in Dengue Virus-Infected Vero Cells Aussara Panya 1,2, Pucharee Songprakhon 3, Suthida Panwong 2, Kanyaluck Jantakee 2, Thida Kaewkod 2, Yingmanee Tragoolpua 2, Nunghathai Sawasdee 3, Vannajan Sanghiran Lee 4, Piyarat Nimmanpipug 1,5,* and Pa-thai Yenchitsomanus 3,* 1 Center of Excellence for Innovation in Analytical Science and Technology, Chiang Mai University, Chiang Mai 50200, Thailand; [email protected] 2 Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand; [email protected] (S.P.); [email protected] (K.J.); [email protected] (T.K.); [email protected] (Y.T.) 3 Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; [email protected] (P.S.); [email protected] (N.S.) 4 Department of Chemistry, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia; [email protected] 5 Department of Chemistry, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand * Correspondence: [email protected] (P.N.); [email protected] (P.-t.Y.) Abstract: Dengue virus (DENV) infection causes mild to severe illness in humans that can lead to fatality in severe cases. Currently, no specific drug is available for the treatment of DENV infection. 0 Thus, the development of an anti-DENV drug is urgently required. Cordycepin (3 -deoxyadenosine), which is a major bioactive compound in Cordyceps (ascomycete) fungus that has been used for Citation: Panya, A.; Songprakhon, P.; centuries in Chinese traditional medicine, was reported to exhibit antiviral activity. However, the Panwong, S.; Jantakee, K.; Kaewkod, anti-DENV activity of cordycepin is unknown.
    [Show full text]
  • The Effect of the Polyadenylation Inhibitor Cordycepin on MCF-7 Cells
    Khurshid, Asma (2015) The effect of the polyadenylation inhibitor Cordycepin on MCF-7 cells. PhD thesis, University of Nottingham. Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/28835/1/PhD%20Thesis%20April%202015%20%28Examiner %20corrections%29.pdf Copyright and reuse: The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions. · Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. · To the extent reasonable and practicable the material made available in Nottingham ePrints has been checked for eligibility before being made available. · Copies of full items can be used for personal research or study, educational, or not- for-profit purposes without prior permission or charge provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. · Quotations or similar reproductions must be sufficiently acknowledged. Please see our full end user licence at: http://eprints.nottingham.ac.uk/end_user_agreement.pdf A note on versions: The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the repository url above for details on accessing the published version and note that access may require a subscription. For more information, please contact [email protected] The effect of the polyadenylation inhibitor Cordycepin on MCF-7 cells Asma Khurshid, MSc (University of Nottingham) Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy July 2015 Declaration Except where acknowledged in the text, I declare that this dissertation is my own work and is based on research that was undertaken by me in the School of Pharmacy, Faculty of Science, University of Nottingham.
    [Show full text]
  • The Genetic Program of Pancreatic Beta-Cell Replication in Vivo
    Page 1 of 65 Diabetes The genetic program of pancreatic beta-cell replication in vivo Agnes Klochendler1, Inbal Caspi2, Noa Corem1, Maya Moran3, Oriel Friedlich1, Sharona Elgavish4, Yuval Nevo4, Aharon Helman1, Benjamin Glaser5, Amir Eden3, Shalev Itzkovitz2, Yuval Dor1,* 1Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 2Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 3Department of Cell and Developmental Biology, The Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel 4Info-CORE, Bioinformatics Unit of the I-CORE Computation Center, The Hebrew University and Hadassah, The Institute for Medical Research Israel- Canada, The Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel 5Endocrinology and Metabolism Service, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel *Correspondence: [email protected] Running title: The genetic program of pancreatic β-cell replication 1 Diabetes Publish Ahead of Print, published online March 18, 2016 Diabetes Page 2 of 65 Abstract The molecular program underlying infrequent replication of pancreatic beta- cells remains largely inaccessible. Using transgenic mice expressing GFP in cycling cells we sorted live, replicating beta-cells and determined their transcriptome. Replicating beta-cells upregulate hundreds of proliferation- related genes, along with many novel putative cell cycle components. Strikingly, genes involved in beta-cell functions, namely glucose sensing and insulin secretion were repressed. Further studies using single molecule RNA in situ hybridization revealed that in fact, replicating beta-cells double the amount of RNA for most genes, but this upregulation excludes genes involved in beta-cell function.
    [Show full text]